Company intelligence / Profile preview

Pebble

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Pebble provides advanced ex-vivo organ perfusion platforms enabling high-fidelity preclinical testing of drugs and devices. Their LIVING‑ORGAN system allows researchers to study human-relevant tissue responses without live animal use. The company also develops its own pipeline of preservation solutions and first-in-class blood purification devices targeting leukocytes/cytokines/complement/electrolytes. No published clinical results yet; focus is on accelerating external clients' drug/device development with submission-ready data.

Therapeutic areas: Immunology
Modalities: Device (LIVING-ORGAN system)Medical device for ex-vivo organ perfusion and blood purification systemsPotentially Small molecule or Biologic
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Pebble.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pebble.

Explore the full profile